兆科眼科-B(06622)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06622 兆科眼科-B

休市中 09-11 16:08:54

2.485

-0.035

-1.39%

最高2.520	最低2.475	成交量11.20万
今开2.515	昨收2.520	日振幅1.79%
总市值13.64亿	流通市值13.64亿	总股本5.49亿
成交额28.00万	换手率0.02%	流通股本5.49亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06622","market":"HK","secType":"STK","nameCN":"兆科眼科-B","latestPrice":2.485,"timestamp":1789114134144,"preClose":2.52,"halted":0,"volume":112000,"delay":0,"changeRate":-0.013888888888888945,"floatShares":549000000,"shares":549000000,"eps":-0.44688465358246654,"marketStatus":"休市中","change":-0.035,"latestTime":"09-11 16:08:54","open":2.515,"high":2.52,"low":2.475,"amount":279987,"amplitude":0.017857,"askPrice":2.52,"askSize":35000,"bidPrice":2.485,"bidSize":4500,"shortable":0,"etf":0,"ttmEps":-0.4588562819535307,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":7,"adr":0,"listingDate":1619625600000,"exchange":"SEHK","adjPreClose":2.52,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"volumeRatio":0.3974156628318181,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06622","defaultTab":"news","newsList":[{"id":"1145652378","title":"兆科眼科-B：YUVEZZI™中国II期临床达主要终点，拟推进III期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1145652378","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145652378?lang=zh_cn&edition=full","pubTime":"2026-09-04 18:46","pubTimestamp":1788518772,"startTime":"0","endTime":"0","summary":"2026年9月4日，兆科眼科-B公告称，其创新药卡巴胆碱酒石酸溴莫尼定滴眼液在中国开展的II期临床研究已达到预先设定的主要研究终点，显示出良好耐受性及安全性。结果显示，YUVEZZI在疗效和安全性方面均达到预期。根据香港联交所证券上市规则第18A.05条，兆科眼科-B提示，尚无法保证最终成功开发或商业化YUVEZZI。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664641336","title":"兆科眼科-B(06622.HK)：卡巴胆硷酒石酸溴莫尼定滴眼液(YUVEZZI™)于中国老花眼患者的第II期研究中达到主要研究终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2664641336","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664641336?lang=zh_cn&edition=full","pubTime":"2026-09-04 18:41","pubTimestamp":1788518460,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1587","BK1191","06622","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159127199","title":"兆科眼科-B8月股份变动月报：已发行股份增至548,839,012股","url":"https://stock-news.laohu8.com/highlight/detail?id=1159127199","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159127199?lang=zh_cn&edition=full","pubTime":"2026-09-02 15:56","pubTimestamp":1788335807,"startTime":"0","endTime":"0","summary":"兆科眼科有限公司于2026年9月2日披露截至2026年8月31日的股份变动月报表。根据公告，公司法定/注册股本与上月保持一致，均为1,600,000,000,000股普通股，每股面值0.00000025美元，法定/注册股本总额持平于400,000美元。报告期初公司已发行普通股共548,749,012股，期间因行使购股权新增发行90,000股，期末已发行普通股增至548,839,012股。在股份期权方面，报告期内按公司首发后购股权计划，因期权行使和失效进行相应调整。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663071315","title":"李氏大药厂(00950)公布中期业绩 拥有人应占溢利9501.4万港元 同比增长41.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663071315","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663071315?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:50","pubTimestamp":1788169857,"startTime":"0","endTime":"0","summary":"智通财经APP讯，李氏大药厂 公布2026年中期业绩，收益约7.97亿港元，同比增长14.6%;公司拥有人应占溢利9501.4万港元，同比增长41.4%;每股盈利16.14港仙，每股中期股息3.5港仙。其中，引进产品的收益增加24.3%至约3.37亿港元，主要源于《菲普利》、《布累迪宁》、《曲特恪》及《芮舒延》的贡献。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489545.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1587","BK1191","00950","BK1583","06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662469091","title":"兆科眼科-B(06622)公布中期业绩 净亏损约1.23亿元 同比增长5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662469091","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662469091?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:45","pubTimestamp":1787928317,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兆科眼科-B(06622)公布2026年中期业绩，收益1882.8万元，同比增长19.14%;净亏损约1.23亿元，同比增长5.12%;每股亏损0.22元。公告称，亏损增长主要是由于银行存款利息收入减少，反映自2025年中以来全球利率下调，以及一般及行政费用中确认的以权益结算以股份为基础的付款开支增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1488604.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","06622","BK1574","BK1587","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169170344","title":"兆科眼科-B(06622)2026年中期营收1,882.80万元，经调整净亏损1.16亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1169170344","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169170344?lang=zh_cn&edition=full","pubTime":"2026-08-28 21:23","pubTimestamp":1787923398,"startTime":"0","endTime":"0","summary":"兆科眼科-B公告显示，2026年上半年营收为1,882.80万元，同比增长19.14%。同期，经调整净亏损为1.16亿元，同比扩大0.72%。公告提及，毛利为974.80万元，同比上升15.12%。在成本结构方面，研发投入约1.06亿元，相比上一年同期的1.13亿元，小幅下降6.46%。一般及行政费用约3,321万元，同比增长8.67%。销售及分销开支约2,482.50万元，同比增长6%。公司公告提到，将在2026年继续推进多款旗舰药物的商业化进程。公司目标是在2026年底或之前拥有合共12款商业化药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"兆科眼科-B(06622)2026年中期营收1,882.80万元，经调整净亏损1.16亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662472467","title":"港股异动 | 李氏大药厂(00950.HK)盈喜后涨超20% 预计中期股东应占纯利约8500万至9500万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662472467","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662472467?lang=zh_cn&edition=full","pubTime":"2026-08-27 10:34","pubTimestamp":1787798089,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1583","00950","BK1574","BK1587","06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662126957","title":"李氏大药厂(00950)发盈喜 预计中期股东应占纯利约8500万至9500万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662126957","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662126957?lang=zh_cn&edition=full","pubTime":"2026-08-26 21:21","pubTimestamp":1787750513,"startTime":"0","endTime":"0","summary":"智通财经APP讯，李氏大药厂(00950)发布公告，集团预期截至2026年6月30日止六个月将取得未经审核股东应占纯利介于约8500万港元至9500万港元，而截至2025年6月30日止六个月则取得约6720万港元。预期集团的中期业绩有所改善，主要源于(其中包括)(i)集团的收益增长;(ii)集团的整体毛利率改善，而此乃归因于产品组合更为理想，其中利润较高之专科及引进产品占比较大，以及集团各生产基地的制造效率持续提升。上述两项因素结合产生的正面影响，足以抵销报告期内所取得研究及开发费用、销售及分销费用以及行政费用(包括与集团新综合入账的美国业务相关的成本)增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","06622","BK1574","BK1583","00950","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144431392","title":"兆科眼科-B（06622）公告8月28日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1144431392","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144431392?lang=zh_cn&edition=full","pubTime":"2026-08-17 16:56","pubTimestamp":1786956968,"startTime":"0","endTime":"0","summary":"兆科眼科-B（06622）8月17日发布董事会会议通告，公司董事会将于2026年8月28日（星期五）召开会议，拟审议并批准公司及其附属公司截至2026年6月30日止六个月的未经审核中期业绩及其刊发事宜。\n本次会议同时将处理与中期业绩相关的其他事项。\n公告显示，截至公告日期，兆科眼科-B董事会成员包括：执行董事李小羿博士、戴向荣先生；非执行董事李烨妮女士、张甜甜女士；独立非执行董事黄显荣先生、卢毓琳教授及刘怀镜先生。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659119634","title":"港股异动 | 李氏大药厂(00950)涨超7% ZK2401于中国提交新药临床试验申请已获NMPA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2659119634","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659119634?lang=zh_cn&edition=full","pubTime":"2026-08-14 15:36","pubTimestamp":1786692986,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，李氏大药厂涨超7%，截至发稿，涨7.27%，报1.18港元，成交额201.32万港元。消息面上，近期，李氏大药厂发布公告，本集团就ZK2401于中国的新药临床试验申请已获得中国国家药品监督管理局药品评审中心受理。ZK2401为李氏大药厂自主研发的专有抗体药物偶联物项目，由李氏大药厂拥有该分子的完整全球知识产权。作为李氏大药厂ADC平台的首个项目，ZK2401标志着本集团推进该平台发展的一个重要起点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479979.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBJ","BK1574","BMED","BK1191","IBBQ","PSYK","VXUS","06622","BK4588","KCAI","BK1587","MDTX","BK4585","00950","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658978682","title":"兆科眼科-B(06622.HK)与澎湃生物医药就盐酸依匹斯汀滴眼液订立独家分销及推广协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2658978682","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658978682?lang=zh_cn&edition=full","pubTime":"2026-08-12 16:55","pubTimestamp":1786524923,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1574","BK1191","06622","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199644797","title":"兆科眼科-B签订盐酸依匹斯汀滴眼液中国内地商业化协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1199644797","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199644797?lang=zh_cn&edition=full","pubTime":"2026-08-12 16:55","pubTimestamp":1786524909,"startTime":"0","endTime":"0","summary":"兆科眼科-B（ZHAOKE OPHTH-B）近日宣布，已签署一项重要协议。该协议旨在中国内地（不含香港、澳门及台湾地区）推进盐酸依匹斯汀滴眼液的商业化进程。此举标志着这家眼科制药企业，在深耕中国市场的道路上又迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622","BK1587","BK1574","BK1583","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657667506","title":"李氏大药厂(00950.HK)转仓市值总计4607.25万港元 占比7.24% 从南洋商业银行转出4243.83万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657667506","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657667506?lang=zh_cn&edition=full","pubTime":"2026-08-07 08:27","pubTimestamp":1786062441,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1587","BK1560","BK1574","BK1583","00950","BK1231","09668","06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155945195","title":"兆科眼科-B公布2026年7月股份变动月报，股本继续维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1155945195","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155945195?lang=zh_cn&edition=full","pubTime":"2026-08-03 13:11","pubTimestamp":1785733909,"startTime":"0","endTime":"0","summary":"兆科眼科有限公司于2026年8月3日发布截至2026年7月31日止月份的证券变动月报。报告显示，公司法定/注册股本维持在1,600,000,000,000股，面值0.00000025美元，总额400,000美元，与上月保持一致。公司已发行普通股股数截至2026年7月31日为548,749,012股，未有新增发行或注销动作，也无库藏股数量变化。公司确认其于本月内的证券发行及库存股份出售或转让均符合香港联交所《上市规则》和有关法律及监管规定。公告由公司董事李小羿签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655059788","title":"李氏大药厂(00950.HK)：专有ADC项目ZK2401于中国提交新药临床试验申请获NMPA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2655059788","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655059788?lang=zh_cn&edition=full","pubTime":"2026-07-30 22:13","pubTimestamp":1785420782,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1587","00950","BK1191","BK1574","06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655846808","title":"一边亏着两个亿，一边押注全球阿托品：兆科眼科的近视神药豪赌","url":"https://stock-news.laohu8.com/highlight/detail?id=2655846808","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655846808?lang=zh_cn&edition=full","pubTime":"2026-07-30 09:10","pubTimestamp":1785373839,"startTime":"0","endTime":"0","summary":"悬崖边上，落子全球棋局。兆科眼科（6622.HK）近日发布自愿性公告称，公司已于2026年6月22日订立最终协议，收购硫酸阿托品滴眼液NVK002的全球权利。据协议条款，兆科眼科将取得与NVK002相关的全部知识产权、商标、监管档案、临床数据、制造能力及其他相关资产的全球拥有权，全面掌控该产品在全球的开发、制造及商业化工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607303825997988.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607303825997988.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06622","BK1587","BK1583","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152918833","title":"兆科眼科-B（06622）老花眼创新药YUVEZZI™获澳门药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1152918833","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152918833?lang=zh_cn&edition=full","pubTime":"2026-07-20 12:06","pubTimestamp":1784520369,"startTime":"0","endTime":"0","summary":"兆科眼科-B7月20日公告称，其创新药YUVEZZI已于2026年7月13日获澳门特别行政区政府药物监督管理局批准，用于治疗老花眼。Tenpoint已于2026年1月获得美国食品药品监督管理局批准，将该药用于治疗通常在45岁左右发病的老花眼。同年6月，海南省药品监督管理局亦批准该药作为博鳌超级医院的临床急需进口药品使用。\\n\\n兆科眼科-B提醒股东及潜在投资者，依据香港联合交易所有限公司证券上市规则第18A.05条，公司无法保证最终能成功开发或商业化该药品。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652028501","title":"李氏大药厂(00950)就干扰素ALPHA-2B产品与ASHLINS订立大中华地区以外独家许可及供应协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2652028501","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652028501?lang=zh_cn&edition=full","pubTime":"2026-07-17 21:36","pubTimestamp":1784295413,"startTime":"0","endTime":"0","summary":"智通财经APP讯，李氏大药厂 发布公告，于2026年7月6日，公司与Ashlins Ocular Pharmaceuticals, Inc. 订立独家许可协议。根据该协议，公司同意向Ashlins许可及供应干扰素Alpha-2b，以供其于中国内地、香港、澳门及台湾以外所有地区开发及商业化用于诊断、预防或治疗若干人类疾病的药品。干扰素Alpha-2b乃一种透过重组DNA技术生产的重组人I型干扰素活性药物成分，用作具有抗病毒及免疫调节活性的药品的活性物质。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469289.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1583","BK1574","00950","06622","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651341039","title":"创新药连续大涨，这次真的不一样了吗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2651341039","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651341039?lang=zh_cn&edition=full","pubTime":"2026-07-16 17:05","pubTimestamp":1784192720,"startTime":"0","endTime":"0","summary":"政策上，医保初审通过率创新高，定价机制优化，并建立“医保+商保”双层支付体系；产业上，上半年BD交易总额达1100亿美元，国际竞争力显著提升；资金面上，内外资持续回流。行业正从“讲故事”转向盈利兑现，国金证券认为，2027年有望成为中国创新药海外商业化集中兑现的重要节点。","market":"hk","thumbnail":"https://static.tigerbbs.com/8daedf52c02cecfd417dcbd813afb3fa","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8daedf52c02cecfd417dcbd813afb3fa"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3777107","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00241","06606","09688","BK1161","IBBQ","09995","01672","06618","02268","09606","06622","MEDX","06978","02359","06996","03347","09966","02137","159992","03759","02269","01801","BK1574"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2651212817","title":"港股公告掘金 | 佑驾创新与滴滴送货建立长期战略合作关系 拟共同推动城市末端无人配送商业化、规模化落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2651212817","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651212817?lang=zh_cn&edition=full","pubTime":"2026-07-14 08:47","pubTimestamp":1783990072,"startTime":"0","endTime":"0","summary":"重大事项：兆科眼科-B(06622)订立最终协议以收购NVK002(硫酸阿托品滴眼液)的全球权利脑动极光-B(06681)荣获第三届雄安垂直大模型应用大赛亚军及最新临床科研成果在国际权威期刊发表胜宏科技(02476)澄清网络不实负面传闻 AI PCB 订单持续增长佑驾创新(02431)与滴滴送货建立长期战略合作关系 拟共同推动城市末端无人配送商业化、规模化落地恒瑞医药(01276)：HRS-705","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1466963.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0516423091.SGD","01336","BK1189","LU1242518857.USD","KCAI","BK4585","LU0173614495.USD","06681","LU1008478684.HKD","LU0880133367.SGD","LU2088748293.HKD","BK4588","LU0738912210.USD","LU1807302812.USD","HK0000306685.HKD","LU0067412154.USD","BK1144","LU0791590937.USD","LU0516422366.SGD","LU2088748020.USD","IE00B3M56506.USD","SG9999014674.SGD","BK1184","HK0000320264.USD","LU0072913022.USD","LU0348827113.USD","LU0650527681.SGD","HK0000320223.HKD","LU0594300179.USD","BK1555","LU0048580855.USD","BK1589","LU0287142896.SGD","LU0370786039.SGD","BK1191","02431","LU0211977185.USD","LU0359202008.SGD","LU0791591158.USD","06622","BK1240","HK0000306701.USD","LU0359201612.USD","01109","LU0516422952.EUR","SG9999009997.SGD","DIDIY","LU0516423174.USD","VXUS","BK1570"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0178},{"period":"1month","weight":-0.002},{"period":"3month","weight":-0.1311},{"period":"6month","weight":-0.2401},{"period":"1year","weight":-0.3693},{"period":"ytd","weight":-0.1605}],"compareEarnings":[{"period":"1week","weight":-0.033},{"period":"1month","weight":-0.0249},{"period":"3month","weight":0.0035},{"period":"6month","weight":-0.0259},{"period":"1year","weight":-0.0491},{"period":"ytd","weight":-0.0322}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"兆科眼科有限公司是一家主要从事眼科药物及产品的开发、生产及营销的投资控股公司。该公司的主要产品包括用于治疗近视的NVK002（阿托品）、用于治疗干眼症的环孢素A眼凝胶以及用于治疗wAMD的TAB014（贝伐单抗）。该公司产品主要用于干眼症（DED）、近视、老花眼、湿性老年黄斑部病变（wAMD）和糖尿病黄斑水肿（DME）、青光眼及角膜上皮细胞功能障碍（CED）等影响眼前节及眼后节的眼科疾病的治疗。该公司在中国国内及海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.147188},{"month":2,"riseRate":0.2,"avgChangeRate":-0.134185},{"month":3,"riseRate":0.2,"avgChangeRate":-0.040318},{"month":4,"riseRate":0.2,"avgChangeRate":0.019445},{"month":5,"riseRate":0.333333,"avgChangeRate":0.015956},{"month":6,"riseRate":0.166667,"avgChangeRate":0.033584},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.047805},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.009984},{"month":9,"riseRate":0.5,"avgChangeRate":0.001933},{"month":10,"riseRate":0.2,"avgChangeRate":-0.082811},{"month":11,"riseRate":0.4,"avgChangeRate":0.029799},{"month":12,"riseRate":0.2,"avgChangeRate":-0.018114}],"exchange":"SEHK","name":"兆科眼科-B","nameEN":"ZHAOKE OPHTH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"兆科眼科-B(06622)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供兆科眼科-B(06622)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"兆科眼科-B,06622,兆科眼科-B股票,兆科眼科-B股票老虎,兆科眼科-B股票老虎国际,兆科眼科-B行情,兆科眼科-B股票行情,兆科眼科-B股价,兆科眼科-B股市,兆科眼科-B股票价格,兆科眼科-B股票交易,兆科眼科-B股票购买,兆科眼科-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"兆科眼科-B(06622)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供兆科眼科-B(06622)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}